Schizophrenia and bipolar disorder exhibit a twin-study heritability rate of 81 percent, yet standard genome-wide association studies capture only about a quarter of this genetic risk, according to a peer-reviewed Perspective in Genomic Psychiatry.
CAG Repeats and Astrocyte Glutamine Overload Drive Psychiatric Risk
- The Missing Piece: Standard genetic tests miss short, stuttering DNA stretches called CAG repeats that may drive much of the unaccounted risk for psychiatric conditions.
- The Astrocyte Load: Support cells in the brain called astrocytes become overloaded with the amino acid glutamine, disrupting normal signaling pathways without destroying neurons.
- Imaging Clues: High-resolution 7-tesla brain scans can now separate glutamate and glutamine signals, revealing distinct metabolic shifts in patients.
Unstable Genes Beyond the Central Dogma
Researchers at Bharati Vidyapeeth Deemed University in Pune, India, assembled a catalogue of 45 human CAG-repeat genes to explain the missing heritability in psychiatric disorders. Mahabaleshwar V. Hegde, along with Asavari A. Joshi, Yogesh S. Badhe, and Anvita A. Kale, initially put forward this framework in 2011 under the title “Unstable Genes Unstable Mind; Beyond the central Dogma of Molecular Biology.”
While genome-wide association studies have successfully pinpointed hundreds of risk loci, they focused on unique sequences while largely ignoring repeat regions. “We propose that cumulative variation across these 45 CAG-repeat genes may be a substantial component of the missing heritability,” Hegde stated. “How large is that component, remains unknown, and it has to be measured directly with repeat-aware genomic approaches.”
Glutamine Overload inside Astrocytes
The authors propose a chain of events running through astrocytes, the support cells that supply neurons with glutamine. When multiple genes produce proteins with enlarged glutamine stretches, astrocytes face an outsized demand for the amino acid. Astrocytes switch on a metabolic side route to make more alpha-ketoglutarate and hold glutamine back instead of exporting it to neurons. Neurons subsequently run short of glutamate, GABA, and the antioxidant glutathione.
Serving as a biological Trojan horse—a concept borrowed from hepatic encephalopathy, where trapped glutamine causes astrocytes to swell and shift into a reactive state—glutamine accumulation inside these support cells drives dysfunction. Reactive astrocytes release inflammatory signals, recruit complement proteins, and eliminate synapses. The authors propose that brain geography dictates the specific illness, with NMDA receptor hypofunction favoring schizophrenia-type symptoms and metabotropic glutamate receptor 5 implicated in bipolar disorder.
| Parameter | Schizophrenia Model | Bipolar Disorder Model |
|---|---|---|
| Primary Receptor Implicated | NMDA Receptor Hypofunction | Metabotropic Glutamate Receptor 5 |
| Metabolic Shift | Elevated Glutamine, Reduced Glutamate | Altered Glutamatergic Signaling |
| Cellular Impact | Astrocyte Swelling and Synapse Loss | Circuit Disruption via Metabolic Burden |
High-Field Spectroscopy and Metabolic Signatures
At 3 tesla and below, glutamate and glutamine signals overlap and were long reported together as a sign of excess glutamate. At 7 tesla, magnetic resonance spectroscopy can separate these signals. Evaluating data from 28 studies that included 647 patients and 608 controls, a meta-analysis determined that levels of glutamine increase while glutamate levels decline in the medial frontal region of individuals with schizophrenia. “These measurements are the most encouraging fit for our model, but they carry a real limitation,” Hegde stated.
“Spectroscopy reports totals for a whole region. Assigning the higher glutamine to astrocytes and the lower glutamate, GABA, and glutathione to neurons is a model-based inference consistent with the data, not something the scans prove directly.”
The framework also attempts to account for genetic anticipation, where illness arrives earlier in later generations, and the observation that men develop schizophrenia three to four years earlier than women through potential instability in the X-linked androgen receptor gene.
Seek Professional Help for Acute Psychiatric Symptoms
This study outlines a theoretical genetic and metabolic hypothesis and does not provide immediate diagnostic tests or clinical treatments for patients. Individuals experiencing acute psychotic symptoms, severe mood swings, or cognitive impairment must seek evaluation from qualified mental health professionals. Standard diagnostic assessments remain essential, as targeted repeat-aware genomic profiling and metabolic interventions are currently investigational and restricted to research settings.
Future Validation and Translational Trajectory
The authors emphasize that the hypothesis requires rigorous experimental validation. The specific repeat-length data needed to quantify how much heritability these 45 genes explain do not yet exist for large schizophrenia and bipolar populations.
Computational tools for profiling tandem repeats across the genome and single-cell transcriptomics mapping are necessary next steps to determine where each candidate gene is expressed. If substantiated, these repeat profiles could yield biological biomarkers to replace subjective diagnostic assessments and point toward early metabolic treatments.
References
- Hegde, M. V., et al. (2026). Polymorphic CAG repeats and missing heritability in schizophrenia and bipolar disorder: A poly-glutamine neurodevelopmental hypothesis. Genomic Psychiatry. DOI: 10.61373/gp026p.0060.
Disclaimer: This article is intended for informational and educational purposes only based on peer-reviewed research published in Genomic Psychiatry and does not constitute medical advice, diagnosis, or treatment.
